In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'HMG-CoA reductase inhibitor / statin'
Please login to view adverse reactions.
Neurological adverse effect / neurological deficit
- (2024): Li J+, Endocr Metab Immune Disord Drug Targets Oct, Online ahead of print (association) (pharmacovigilance / pharmacoepidemiology)
- (2022): Attardo S+, Int J Mol Sci 23(15), 8364 [REVIEW]
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
- (2023): Su FY+, Horm Metab Res Nov, Online ahead of print (with concomitant medication)
Myalgia/Myositis/Myopathy/Myotoxicity
- (2025): Sridharan K+, Curr Rev Clin Exp Pharmacol Mar, Online ahead of print [REVIEW] (pharmacogenomics)
- (2023): Wei C+, J Clin Med 12(10), 3548 (with daptomycin; association)
- (2023): Yow HY+, Asian Biomed (Res Rev News) 17(3), 95-114 [REVIEW] (pharmacogenomics)
- (2023): Drug Ther Bull Dec, Online ahead of print (UK MHRA; September 2023; Statins: very infrequent reports of myasthenia gravis. Globally, there has been a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis with atorvastatin, pravastatin, lovastatin, fluvastatin, simvastatin, rosuvastatin and pitavastatin (single-ingredient and fixed-dose combination products). Advise patients taking statins to be alert to new symptoms for myasthenia gravis, or worsening symptoms of pre-existing myasthenia gravis, and to seek medical advice if these occur.)
Necrotizing myopathy / immune-mediated necrotizing myopathy
- (2022): Somagutta MKR+, Reumatologia 60(1), 63-69 [REVIEW]
- (2017): Tiniakou E+, Curr Opin Rheumatol 29(6), 604-611 [REVIEW]
- (2022): Kunakorntham P+, BMC Med Inform Decis Mak 22(1), 233
- (2015): Bahrami B+, Med J Aust 203(9), 365 [REVIEW]
- (2015): Mizranita V+, Int J Clin Pharm 37(5), 844-50 [REVIEW]
